Tony R Reid - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Tony R Reid

Showing results (51-60 of 56) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 56 results.

Future Oncology (London, England)|September 12, 2019

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.

Clinical Medicine Insights. Oncology|November 15, 2016

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.

Cancer|April 23, 2013

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 studyJeffrey R Infante, Tony R Reid, Allen L Cohn, et al.

Cancer Gene Therapy|December 25, 2023

BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.

Case Reports in Oncology|May 18, 2017

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological TumorChristina Brzezniak, Bryan Oronsky, Jane Trepel, et al.

Expert Opinion on Investigational Drugs|December 10, 2016

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.

Pageof 6

Search research articles

Showing results (51-60 of 56) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 56 results.

Future Oncology (London, England)|September 12, 2019

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.

Clinical Medicine Insights. Oncology|November 15, 2016

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.

Cancer|April 23, 2013

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 studyJeffrey R Infante, Tony R Reid, Allen L Cohn, et al.

Cancer Gene Therapy|December 25, 2023

BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.

Case Reports in Oncology|May 18, 2017

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological TumorChristina Brzezniak, Bryan Oronsky, Jane Trepel, et al.

Expert Opinion on Investigational Drugs|December 10, 2016

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.

Pageof 6